Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter, Open Label, Sponsor Blinded, Randomized, Active Controlled, Parallel Group, Pivotal Study to Evaluate the Efficacy, Safety, and Tolerability of Murepavadin Given With Ertapenem Versus an Anti-pseudomonal-β-lactam-based Antibiotic in Adult Subjects With Nosocomial Pneumonia Suspected or Confirmed to be Due to Pseudomonas Aeruginosa

Trial Profile

A Multicenter, Open Label, Sponsor Blinded, Randomized, Active Controlled, Parallel Group, Pivotal Study to Evaluate the Efficacy, Safety, and Tolerability of Murepavadin Given With Ertapenem Versus an Anti-pseudomonal-β-lactam-based Antibiotic in Adult Subjects With Nosocomial Pneumonia Suspected or Confirmed to be Due to Pseudomonas Aeruginosa

Recruiting
Phase of Trial: Phase III

Latest Information Update: 10 Feb 2019

At a glance

  • Drugs Ertapenem (Primary) ; Murepavadin (Primary) ; Meropenem; Piperacillin/tazobactam
  • Indications Nosocomial pneumonia; Pseudomonal infections
  • Focus Registrational; Therapeutic Use
  • Acronyms PRISM-UDR
  • Sponsors Polyphor
  • Most Recent Events

    • 24 Oct 2018 According to a Polyphor media release, the company has reached agreement with the U.S. Food and Drug Administration (FDA) on protocol of the trial. With the agreed protocol, the FDA requested not to proceed with an interim analysis for the intention of stopping the trial early due to the small sample size. Therefore, the basis for a potential registration in the United States will be the completion of the single pivotal Phase III study, PRISM-UDR.
    • 24 Oct 2018 According to a Polyphor media release, the company expects to recruit the first patient by Q1 19. The miTT population will comprise 210 evaluable subjects (105 subjects per arm) with nosocomial pneumonia confirmed to be due to Pseudomonas aeruginosa.
    • 24 Oct 2018 Status changed from not yet recruiting to recruiting, according to a Polyphor media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top